| abstract |
Provided herein are methods for identifying risk of melanoma in a subject and/or subjects at risk of melanoma, reagents and kits for carrying out the methods, methods for identifying candidate therapeutics for treating melanoma, therapeutic methods for treating melanoma in a subject and compositions comprising one or more melanoma cells and one or more NRP1, NID2, ENDO180, CDK10, FPGT, CARK, PCLO or REPS2 directed agents. These embodiments are based upon an analysis of polymorphic variations in a NRP1, NID2, ENDO180, CDK10, FPGT, CARK, PCLO or REPS2 nucleic acid, exemplified by nucleotide sequences of SEQ ID NO: 1-17. |